PMID- 29660202
OWN - NLM
STAT- MEDLINE
DCOM- 20180619
LR  - 20220330
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 109
IP  - 6
DP  - 2018 Jun
TI  - Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
PG  - 1743-1752
LID - 10.1111/cas.13613 [doi]
AB  - Uterine leiomyosarcoma (u-LMS) and endometrial stromal sarcoma (ESS) are among 
      the most frequent soft tissue sarcomas, which, in adults, lead to fatal lung 
      metastases and patients have an extremely poor prognosis. Due to their rarity and 
      heterogeneity, there are no suitable biomarkers for diagnosis and prognosis, 
      although some biomarker candidates have appeared. In 2017, The Cancer Genome 
      Atlas (TCGA) Research Network's work on u-LMS has confirmed mutations and 
      deletions in RB1, TP53 and PTEN. In addition, whole-exome sequencing of u-LMS has 
      confirmed and demonstrated frequent alterations in TP53, RB1, 
      alpha-thalassemia/mental retardation syndrome X-linked (ATRX) and mediator complex 
      subunit 12 (MED12). MED12 is a useful biomarker to diagnose uterine-derived LMS 
      and tumors arising from (LM) with a relatively favorable prognosis. TP53 and ATRX 
      mutations can be important mechanisms in the pathogenesis of u-LMS and are 
      correlated with a poor prognosis. In an update based on the 2014 WHO 
      classification, low-grade ESS is often associated with gene rearrangement 
      bringing about the JAZF 1-SUZ12 (formerly JAZF1-JJAZ1) fusion gene, whereas 
      high-grade ESS is associated with the YWHAE-NUTM fusion gene. Low-grade ESS with 
      JAZF1 rearrangement may correlate with metastasis. However, high-grade ESS with 
      metastasis with YWHAE rearrangement shows a relatively favorable prognosis. The 
      genetic/molecular genetic aberrations in u-LMS and ESS are reviewed, focusing on 
      molecular biomarkers for these primary and metastatic tumors.
CI  - (c) 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Tsuyoshi, Hideaki
AU  - Tsuyoshi H
AD  - Faculty of Medical Sciences, Department of Obstetrics and Gynecology, University 
      of Fukui, Fukui, Japan.
FAU - Yoshida, Yoshio
AU  - Yoshida Y
AUID- ORCID: 0000-0003-0769-0385
AD  - Faculty of Medical Sciences, Department of Obstetrics and Gynecology, University 
      of Fukui, Fukui, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180523
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RB1 protein, human)
RN  - 0 (Retinoblastoma Binding Proteins)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Female
MH  - Humans
MH  - Leiomyosarcoma/diagnosis/*genetics
MH  - Oncogene Proteins, Fusion/genetics
MH  - PTEN Phosphohydrolase/genetics
MH  - Retinoblastoma Binding Proteins/genetics
MH  - Sarcoma, Endometrial Stromal/diagnosis/*genetics
MH  - Tumor Suppressor Protein p53/genetics
MH  - Ubiquitin-Protein Ligases/genetics
MH  - Uterine Neoplasms/diagnosis/*genetics
PMC - PMC5989874
OTO - NOTNLM
OT  - The Cancer Genome Atlas project
OT  - endometrial stromal sarcoma
OT  - genetic aberrations
OT  - uterine leiomyosarcoma
EDAT- 2018/04/17 06:00
MHDA- 2018/06/21 06:00
PMCR- 2018/06/01
CRDT- 2018/04/17 06:00
PHST- 2018/01/10 00:00 [received]
PHST- 2018/04/07 00:00 [revised]
PHST- 2018/04/09 00:00 [accepted]
PHST- 2018/04/17 06:00 [pubmed]
PHST- 2018/06/21 06:00 [medline]
PHST- 2018/04/17 06:00 [entrez]
PHST- 2018/06/01 00:00 [pmc-release]
AID - CAS13613 [pii]
AID - 10.1111/cas.13613 [doi]
PST - ppublish
SO  - Cancer Sci. 2018 Jun;109(6):1743-1752. doi: 10.1111/cas.13613. Epub 2018 May 23.